↓ Skip to main content

High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma?

Overview of attention for article published in Clinical Sarcoma Research, October 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 X user
f1000
1 research highlight platform

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
21 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma?
Published in
Clinical Sarcoma Research, October 2015
DOI 10.1186/s13569-015-0038-7
Pubmed ID
Authors

Alberto Righi, Anna Paioli, Angelo Paolo Dei Tos, Marco Gambarotti, Emanuela Palmerini, Manuela Cesari, Emanuela Marchesi, Davide Maria Donati, Piero Picci, Stefano Ferrari

Abstract

High-grade foci (grade 3 according to Broder's grading system) are sometimes detected in low-grade (grade 1 and 2) central osteosarcoma. The aim of this study was to retrospectively evaluate the clinical outcome in patients upgraded to high grade (grade 3) after a first diagnosis of low-grade osteosarcoma, following the detection of high-grade areas (grade 3) in the resected specimen. Of the 132 patients with a diagnosis of low-grade central osteosarcoma at surgical biopsy at our Institute, 33 patients were considered eligible for the study. Median age was 37 (range 13-58 years). Location was in an extremity in 29 patients (88 %). Post-operative chemotherapy was given in 22 (67 %) patients. Follow-up data were available for all patients, with a median observation time of 115 months (range 4-322 months). After histological revision, areas of high-grade (grade 3) osteosarcoma accounting for less than 50 % of the tumor were found in 20 (61 %) patients, whereas the majority of the tumor was composed of a high-grade (grade 3) component in 13 (39 %) patients. In the 20 cases of low-grade osteosarcoma with high-grade foci (grade 3) in less than 50 % of the tumor, 9 patients did not receive adjuvant chemotherapy; only one of them died, of unrelated causes. In the adjuvant chemotherapy group (11 out of 20 patients), one patient developed multiple lung metastases and died of disease 39 months after the first diagnosis. In the other 13 cases of low-grade osteosarcoma with high-grade foci (grade 3) in more than 50 % of the tumor, 12 patients received adjuvant chemotherapy: 2 had recurrence, 4 developed multiple lung metastases and 3 died of disease. The only patient who did not receive chemotherapy is alive without disease 232 months after complete surgical remission. Our data indicate that patients with a diagnosis of low-grade osteosarcoma where the high-grade (grade 3) component is lower than 50 % of the resected specimen, may not require chemotherapy, achieving high survival rates by means of complete surgical resection only.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 14%
Researcher 3 14%
Student > Ph. D. Student 3 14%
Other 2 10%
Student > Bachelor 2 10%
Other 2 10%
Unknown 6 29%
Readers by discipline Count As %
Medicine and Dentistry 9 43%
Agricultural and Biological Sciences 1 5%
Veterinary Science and Veterinary Medicine 1 5%
Immunology and Microbiology 1 5%
Materials Science 1 5%
Other 0 0%
Unknown 8 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 August 2021.
All research outputs
#15,867,545
of 23,577,761 outputs
Outputs from Clinical Sarcoma Research
#57
of 103 outputs
Outputs of similar age
#169,148
of 286,371 outputs
Outputs of similar age from Clinical Sarcoma Research
#2
of 3 outputs
Altmetric has tracked 23,577,761 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 103 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,371 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.